Dankert André, Neumann-Schirmbeck Benedikt, Dohrmann Thorsten, Greiwe Gillis, Plümer Lili, Löser Benjamin, Sehner Susanne, Zöllner Christian, Petzoldt Martin
From the Department of Anesthesiology, Center of Anesthesiology and Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Department of Anesthesiology and Intensive Care Medicine, University Medical Center Rostock, Rostock, Germany.
Anesth Analg. 2023 Oct 1;137(4):806-818. doi: 10.1213/ANE.0000000000006235. Epub 2022 Nov 1.
Pulmonary function tests (PFTs) such as spirometry and blood gas analysis have been claimed to improve preoperative pulmonary risk assessment, but the scientific literature is conflicting. The Preoperative Diagnostic Tests for Pulmonary Risk Assessment in Chronic Obstructive Pulmonary Disease (PREDICT) study aimed to determine whether preoperative PFTs improve the prediction of postoperative pulmonary complications (PPCs) in patients with known or suspected chronic obstructive pulmonary disease (COPD) undergoing major surgery. A secondary aim was to determine whether the Global Initiative for Chronic Obstructive Lung Diseases (GOLD) classification of airflow limitation severity (grades I-IV) is associated with PPC.
In this prospective, single-center study, patients with GOLD key indicators for COPD scheduled for major surgery received PFTs. Patients with confirmed COPD (forced expiratory volume in 1 second [FEV1]/forced vital capacity [FVC] ≤0.7) were included in the COPD cohort and compared with a reference cohort without COPD. We developed 3 multivariable risk prediction models and compared their ability to predict PPC: the "standard model" (medical preconditions, and sociodemographic and surgical data), the "COPD assessment model" (additional GOLD key indicators, pack-years, and poor exercise capacity), and the "PFT model" (additional PFT parameters selected by adaptive least absolute shrinkage and selection operator [LASSO] regression). Multiple LASSO regressions were used for cross-validation.
A total of 31,714 patients were assessed for eligibility; 1271 individuals received PFTs. Three hundred twenty patients (240 with confirmed COPD: 78 GOLD I, 125 GOLD II, 28 GOLD III, 9 GOLD IV, and 80 without COPD) completed follow-up. The diagnostic performance was similar among the standard model (cross-validated area under the curve [cvAUC], 0.723; bias-corrected bootstrapped [bc-b] 95% confidence interval [CI], 0.663-0.775), COPD assessment model (cvAUC, 0.724; bc-b 95% CI, 0.662-0.777), and PFT model (cvAUC, 0.729; bc-b 95% CI, 0.668-0.782). Previously known COPD was an independent predictor in the standard and COPD assessment model. %FEV1 PRED was the only PFT parameter selected by LASSO regression and was an independent predictor in the PFT model (adjusted odds ratios [OR], 0.98; 95% CI, 0.967-.0.998; P = .030). The risk for PPC significantly increased with GOLD grades ( P < .001). COPD was newly diagnosed in 53.8% of the patients with confirmed COPD; however, these individuals were not at increased risk for PPC ( P = .338).
COPD is underdiagnosed in surgical patients. Patients with newly diagnosed COPD commonly presented with low GOLD severity grades and were not at higher risk for PPC. Neither a structured COPD-specific assessment nor preoperative PFTs added incremental diagnostic value to the standard clinical preassessment in patients with known or suspected COPD. Unnecessary postponement of surgery and undue health care costs can be avoided.
肺功能测试(PFTs),如肺活量测定和血气分析,据称可改善术前肺部风险评估,但科学文献的观点存在冲突。慢性阻塞性肺疾病(COPD)术前肺部风险评估诊断试验(PREDICT)研究旨在确定术前肺功能测试是否能改善对已知或疑似患有慢性阻塞性肺疾病且即将接受大手术患者术后肺部并发症(PPCs)的预测。次要目的是确定慢性阻塞性肺疾病全球倡议组织(GOLD)对气流受限严重程度的分类(I-IV级)是否与术后肺部并发症相关。
在这项前瞻性单中心研究中,计划接受大手术且符合GOLD COPD关键指标的患者接受了肺功能测试。确诊为COPD(1秒用力呼气容积[FEV1]/用力肺活量[FVC]≤0.7)的患者被纳入COPD队列,并与无COPD的参照队列进行比较。我们开发了3种多变量风险预测模型,并比较它们预测术后肺部并发症的能力:“标准模型”(医疗前提条件、社会人口统计学和手术数据)、“COPD评估模型”(额外的GOLD关键指标、吸烟包年数和运动能力差)以及“肺功能测试模型”(通过自适应最小绝对收缩和选择算子[LASSO]回归选择的额外肺功能测试参数)。使用多个LASSO回归进行交叉验证。
共评估了31714例患者的 eligibility;1271例接受了肺功能测试。320例患者(240例确诊为COPD:78例GOLD I级,125例GOLD II级,28例GOLD III级,9例GOLD IV级,80例无COPD)完成了随访。标准模型(交叉验证曲线下面积[cvAUC],0.723;偏差校正自抽样[bc-b]95%置信区间[CI],0.663-0.775)、COPD评估模型(cvAUC,0.724;bc-b 95% CI,0.662-0.777)和肺功能测试模型(cvAUC,0.729;bc-b 95% CI,0.668-0.782)之间的诊断性能相似。先前已知的COPD在标准模型和COPD评估模型中是独立预测因素。%FEV1预测值是LASSO回归选择的唯一肺功能测试参数,并且在肺功能测试模型中是独立预测因素(调整后的优势比[OR],0.98;95% CI,0.967-0.998;P = 0.030)。术后肺部并发症的风险随GOLD分级显著增加(P < 0.001)。53.8%确诊为COPD的患者新诊断出COPD;然而,这些个体术后肺部并发症的风险并未增加(P = 0.338)。
外科手术患者中COPD诊断不足。新诊断出COPD的患者通常GOLD严重程度分级较低,术后肺部并发症风险不高。对于已知或疑似患有COPD的患者,结构化的COPD特异性评估和术前肺功能测试均未为标准临床预评估增加额外的诊断价值。可以避免不必要的手术延期和不必要的医疗费用。